Powder: -20°C for 3 years | In solvent: -80°C for 1 year
INCB-057643 是一种有效的、选择性的和口服生物可利用的 BET 抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 622 | 现货 | ||
2 mg | ¥ 913 | 现货 | ||
5 mg | ¥ 1,530 | 现货 | ||
10 mg | ¥ 2,290 | 现货 | ||
25 mg | ¥ 3,830 | 现货 | ||
50 mg | ¥ 5,460 | 现货 | ||
100 mg | ¥ 7,450 | 现货 | ||
500 mg | ¥ 14,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,430 | 现货 |
产品描述 | INCB057643 is a potent, selective and orally bioavailable BET inhibitor. |
体外活性 | INCB057643 inhibited binding of BRD2/BRD3/BRD4 to an acetylated histone H4 peptide in the low nM range and was selective against other bromodomain-containing proteins. INCB057643 inhibited proliferation of human AML, DLBCL, and multiple myeloma cell lines, with a corresponding decrease in MYC protein levels. Cell cycle analyses indicated that G1 arrest and a concentration-dependent increase in apoptosis were seen within 48 hours of treatment with INCB057643. BRD proteins also regulate the expression of many pro-inflammatory genes. Production of several cytokines, including IL-6, IL-10 and MIP-1α, was repressed by INCB057643 in human and mouse whole blood stimulated ex vivo with LPS [1]. |
体内活性 | Oral administration of INCB057643 resulted in significant anti-tumor efficacy in xenograft models of AML, myeloma, and DLBCL. Additionally, combining INCB057643 with the standard of care agents used for the treatment of DLBCL including rituximab and bendamustine resulted in enhanced anti-tumor efficacy relative to that achieved with single-agent therapies at doses that were well tolerated [1]. |
分子量 | 415.46 |
分子式 | C20H21N3O5S |
CAS No. | 1820889-23-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (144.42 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.407 mL | 12.0349 mL | 24.0697 mL | 60.1743 mL |
5 mM | 0.4814 mL | 2.407 mL | 4.8139 mL | 12.0349 mL | |
10 mM | 0.2407 mL | 1.2035 mL | 2.407 mL | 6.0174 mL | |
20 mM | 0.1203 mL | 0.6017 mL | 1.2035 mL | 3.0087 mL | |
50 mM | 0.0481 mL | 0.2407 mL | 0.4814 mL | 1.2035 mL | |
100 mM | 0.0241 mL | 0.1203 mL | 0.2407 mL | 0.6017 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
INCB-057643 1820889-23-3 Apoptosis Chromatin/Epigenetic Epigenetic Reader Domain inhibit Inhibitor INCB057643 INCB 057643 inhibitor